Ophthalmologica

Original Paper

Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study

Hatz K.a-c · Schneider U.c · Henrich P.B.c · Braun B.c · Sacu S.d · Prünte C.a-d

Author affiliations

aVista Klinik, Binningen, bDepartment of Ophthalmology, Kantonsspital Liestal, Liestal, and cDepartment of Ophthalmology, University of Basel, Basel, Switzerland; dDepartment of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria

Keywords: Age-related macular degenerationAnti-VEGFPhotodynamic therapy

Related Articles for ""
Ophthalmologica 2015;233:66-73
https://doi.org/10.1159/000367603

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: August 07, 2014
Accepted: August 11, 2014
Published online: November 29, 2014
Issue release date: February 2015

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Abstract

Purpose: To investigate the injection frequency and visual acuity (VA) outcomes with combination therapy (ranibizumab plus verteporfin photodynamic therapy, PDT) versus monotherapy (ranibizumab). Methods: A total of 40 patients with exudative age-related macular degeneration were randomized 1:1 to ranibizumab 0.3 mg plus single standard verteporfin PDT or ranibizumab 0.3 mg plus sham PDT. Ranibizumab was administered 3 times monthly followed by ‘as needed' to month 12 based on predetermined vision/anatomical criteria. Retreatment rates, VA outcomes and safety were assessed. Results: During months 3-12, combination therapy patients required fewer ranibizumab injections (mean 1.3) compared with monotherapy patients (2.8). Mean VA improved by 9.0 letters with combination therapy versus 7.5 letters in the monotherapy group at month 12. Both treatment regimens were well tolerated. Conclusion: The need for ranibizumab retreatment might be reduced by administering a single verteporfin PDT on the same day as the first ranibizumab injection, without compromising VA outcomes or safety.

© 2014 S. Karger AG, Basel



Related Articles:

References

  1. Schmidt-Erfurth U, Hasan T: Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214.
    External Resources
  2. Bressler NM: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119:198-207.
    External Resources
  3. Verteporfin in Photodynamic Therapy (VIP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-560.
    External Resources
  4. Augustin AJ, Schmidt-Erfurth U: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22.
    External Resources
  5. Ozkiris A: Anti-VEGF agents for age-related macular degeneration. Expert Opin Ther Pat 2010;20:103-118.
    External Resources
  6. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G; SUSTAIN Study Group: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-671.
    External Resources
  7. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
    External Resources
  8. Kaiser PK: Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 2007;23:477-487.
    External Resources
  9. Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Lüke M, Bartz-Schmidt KU, Grisanti S: Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006;142:95-104.
    External Resources
  10. Lazic R, Gabric N: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185.
    External Resources
  11. Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, Bailey CC: A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2010;24:1561-1567.
    External Resources
  12. Giustolisi R, Fantozzi N, Staltari M, Marchiori J, Mastrangelo O, Marcucci R, Mirra F, Mazzotta P, Gabrieli CB: Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration. Digit J Ophthalmol 2011;17:23-30.
    External Resources
  13. Bashshur ZF, Schakal AR, El Mollayess GM, Arafat S, Jaafar D Salti HI: Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. Retina 2011;31:636-644.
    External Resources
  14. Krebs I, Vécsei Marlovits V, Bodenstorfer J, Glittenberg C, Ansari Shahrezaei S, Ristl R, Binder S: Comparison of ranibizumab monotherapy versus combination of ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Acta Ophthalmol 2013;91:e178-e183.
    External Resources
  15. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A; DENALI Study Group: Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012;119:1001-1010.
    External Resources
  16. Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A; MONT BLANC Study Group: Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012;119:992-1000.
    External Resources
  17. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-4480.
    External Resources
  18. Novartis Europharm Ltd: Lucentis® (ranibizumab) Summary of Product Characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/000715/WC500043546.pdf (accessed April 15, 2013).
  19. Holm S: A simple sequentially rejective multiple test procedure. Scand J Statist 1979;6:65-70.
  20. Zhang J, Quan H, Ng J, Stepanavage ME: Some statistical methods for multiple endpoints in clinical trials. Control Clin Trials 1997;18:204-221.
    External Resources
  21. Dewi NA, Yuzawa M, Tochigi K, Kawamura A, Mori R: Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area. Jpn J Ophthalmol 2008;52:277-281.
    External Resources
  22. Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, Wolf S: Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration. Acta Ophthalmol 2011;89:585-590.
    External Resources
  23. Sacu S, Varga A, Michels S, Weigert G, Polak K, Vécsei-Marlovits PV, Schmidt-Erfurth U: Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study. Br J Ophthalmol 2008;92:1347-1351.
    External Resources
  24. Chen E, Brown DM, Wong TP, Benz MS, Kegley E, Cox J, Fish RH, Kim RY: Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin Ophthalmol 2010;4:1073-1079.
    External Resources
  25. Cruess AF, Zlateva G, Pleil AM, Wirostko B: Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol 2009;87:118-132.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: August 07, 2014
Accepted: August 11, 2014
Published online: November 29, 2014
Issue release date: February 2015

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2015, Vol.233, No. 2

February 2015

Article

Recommend This
TOP